Luye Pharma Group (FRA:LUP) Margin of Safety % (DCF Earnings Based): N/A (As of Jul. 03, 2026)


FRA:LUP Luye Pharma Group Ltd FRA:LUP
47 GF Score
Price €0.20
GF Value €0.32
Valuation Possible Value Trap
! 5 Warning Signs
View Full Analysis

What is Luye Pharma Group Margin of Safety % (DCF Earnings Based)?

Margin of Safety % (DCF Earnings Based) = (Intrinsic Value: DCF (Earnings Based) - Current Price) / Intrinsic Value: DCF (Earnings Based).

Note: Discounted Earnings model is only suitable for predictable companies (Business Predictability Rank higher than 1-Star). If the company's Predictability Rank is 1-Star or Not Rated, result may not be accurate due to the low predictability of business and the data will not be stored into our database.

Luye Pharma Group's Predictability Rank is 1-Star. Thus, the DCF related results in the screener and portfolio will appear as zero and Margin of Safety % (DCF Earnings Based) is not calculated.

FRA:LUP vs ZTS, UTHR: Margin of Safety % (DCF Earnings Based) Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Luye Pharma Group's Margin of Safety % (DCF Earnings Based), along with its competitors' market caps and Margin of Safety % (DCF Earnings Based) data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Luye Pharma Group Margin of Safety % (DCF Earnings Based) vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Luye Pharma Group's Margin of Safety % (DCF Earnings Based) distribution charts can be found below:

* The bar in red indicates where Luye Pharma Group's Margin of Safety % (DCF Earnings Based) falls into.


FRA:LUP
47GF Score
Luye Pharma Group Ltd FRA:LUP
Margin of Safety % (DCF Earnings Based) is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Luye Pharma Group (FRA:LUP) Overvalued in 2026?

Based on GuruFocus' analysis, Luye Pharma Group stock appears to be undervalued. The current stock price of €0.20 is trading 36.3% below its estimated GF Value™ of €0.32. GuruFocus considers Luye Pharma Group to be Possible Value Trap.

Key valuation signals for FRA:LUP:

  • Margin of Safety % (DCF Earnings Based): N/A
  • GF Value™: €0.32 vs. price of €0.20 (36.3% below fair value)
  • GF Score™: 47/100 with 5 warning signs

No single metric tells the full story. See the FRA:LUP stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Luye Pharma Group Business Description

Other Exchanges LYPHF:USA02186:Hong Kong
Address Hongqiao Road 1438, 22nd Floor, Gubei International Fortune Center II, Changning District, Shanghai, CHN
Luye Pharma Group Ltd is a China-based drug manufacturer that focuses on development, production, marketing and sale of pharmaceutical products. The company develops drugs related to diagnosing and treating cancer, the cardiovascular system, the alimentary tract, and the central nervous system. The company develops drugs for world-wide use in Asia, Europe, and the United States. The Group organizes its business segments by type of products. Oncology drugs, which derives maximum revenue; Cardiovascular system drugs; Alimentary tract and metabolism drugs; Central nervous system drugs; and others. Geographically, the group derives maximum revenue from Chinese Mainland, while it also has its presence in Asia (other than the Chinese mainland), European Union, and Other countries.
47GF Score

Get the complete analysis for FRA:LUP

Margin of Safety % (DCF Earnings Based) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.20
Price
€0.32
GF Value